November 22, 2016 - By Richard Conner · 0 Comments
The stock of Zynerba Pharmaceuticals Incorporated (NASDAQ:ZYNE) registered an increase of 2.24% in short interest. ZYNE’s total short interest was 849,700 shares in November as published by FINRA. Its up 2.24% from 831,100 shares, reported previously. With 178,400 shares average volume, it will take short sellers 5 days to cover their ZYNE’s short positions. The short interest to Zynerba Pharmaceuticals Incorporated’s float is 15.91%. About 15,139 shares traded hands. Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) has risen 57.32% since April 20, 2016 and is uptrending. It has outperformed by 52.76% the S&P500.
Zynerba Pharmaceuticals, Inc. is a specialty pharmaceutical firm focused on developing and commercializing synthetic cannabinoid therapeutics formulated for transdermal delivery. The company has a market cap of $144.69 million. The Firm is evaluating approximately two product candidates, ZYN002 and ZYN001, in over five indications. It currently has negative earnings. The Firm intends to study ZYN002 in patients with refractory epilepsy, osteoarthritis and Fragile X syndrome.
Out of 5 analysts covering Zynerba Pharmaceuticals (NASDAQ:ZYNE), 5 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Zynerba Pharmaceuticals has been the topic of 7 analyst reports since August 31, 2015 according to StockzIntelligence Inc. Canaccord Genuity initiated the shares of ZYNE in a report on Monday, September 14 with “Buy” rating. Oppenheimer initiated the stock with “Outperform” rating in Tuesday, September 8 report. The stock of Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) earned “Buy” rating by H.C. Wainwright on Friday, October 7. The firm earned “Outperform” rating on Thursday, November 12 by Oppenheimer. Jefferies initiated the stock with “Buy” rating in Monday, August 31 report. Piper Jaffray initiated Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) on Monday, August 31 with “Overweight” rating.
Zynerba Pharmaceuticals, Inc., incorporated on January 31, 2007, is a specialty pharmaceutical firm focused on developing and commercializing synthetic cannabinoid therapeutics formulated for transdermal delivery. The Firm is evaluating approximately two product candidates, ZYN002 and ZYN001, in over five indications.
Another recent and important Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) news was published by Marketwatch.com which published an article titled: “/quotes/zigman/3870025/realtime” on July 03, 2015.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Richard Conner